Comparing Two and Three Cycles of Modified TPF Chemotherapy Combined with Camrelizumab for Locally Advanced Nasopharyngeal Carcinoma in a Phase II Study

What this Trial Is About

Researchers are evaluating treatment options for patients with locally advanced nasopharyngeal carcinoma to compare the tumor response and long-term survival outcomes between two cycles and three cycles of induction chemotherapy combined with immunotherapy. This phase II, multicenter, randomized controlled study aims to provide insights into whether fewer cycles of chemotherapy combined with camrelizumab can achieve similar results with potentially fewer side effects. The study compares two treatment groups one receiving two cycles of induction chemotherapy plus immunotherapy, and the other receiving three cycles of the same regimen. Each cycle lasts 21 days and includes drugs nab-paclitaxel, cisplatin, and oral S1 at doses adjusted by body surface area, along with camrelizumab administered intravenously on day 1 of each cycle. This design follows recent guidelines recommending immunotherapy during induction therapy for this cancer. Participants will undergo evaluations of their tumor response at the end of their assigned cycles. Researchers will also monitor survival outcomes over three years, including progression-free survival and overall survival. Regular assessments will include laboratory tests, imaging to measure tumor response, and monitoring for adverse effects. The total study duration extends through long-term follow-up to assess outcomes and safety.

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC